171 related articles for article (PubMed ID: 32252690)
1. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
Sano K; Nakadate K; Hanada K
BMC Cancer; 2020 Apr; 20(1):279. PubMed ID: 32252690
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives.
Sartori G; Belluomini L; Lombardo F; Avancini A; Trestini I; Vita E; Tregnago D; Menis J; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2020 Jul; 20(7):531-542. PubMed ID: 32529917
[TBL] [Abstract][Full Text] [Related]
3. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
5. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in
Abdallah SM; Hirsh V
Curr Oncol; 2018 Jun; 25(Suppl 1):S9-S17. PubMed ID: 29910643
[TBL] [Abstract][Full Text] [Related]
6. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
8. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Engle JA; Kolesar JM
Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
[TBL] [Abstract][Full Text] [Related]
9. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
[TBL] [Abstract][Full Text] [Related]
10. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
[TBL] [Abstract][Full Text] [Related]
11. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Hata A; Katakami N; Kaji R; Yokoyama T; Kaneda T; Tamiya M; Inoue T; Kimura H; Yano Y; Tamura D; Morita S; Negoro S; The Hanshin Oncology Group F
Cancer; 2018 Oct; 124(19):3830-3838. PubMed ID: 30192383
[TBL] [Abstract][Full Text] [Related]
12. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
13. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.
Ricciuti B; Baglivo S; De Giglio A; Chiari R
Ther Adv Respir Dis; 2018; 12():1753466618808659. PubMed ID: 30355049
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
15. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
16. Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
Oashi A; Yasuda H; Kobayashi K; Tani T; Hamamoto J; Masuzawa K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
Mol Cancer Ther; 2019 Sep; 18(9):1593-1601. PubMed ID: 31253648
[No Abstract] [Full Text] [Related]
17. Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Goto A; Ozawa Y; Koda K; Akahori D; Koyauchi T; Amano Y; Kakutani T; Sato Y; Hasegawa H; Matsui T; Yokomura K; Suda T
Respir Investig; 2018 Mar; 56(2):179-183. PubMed ID: 29548657
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect.
Nuvola G; Dall'Olio FG; Melotti B; Sperandi F; Ardizzoni A
J Thorac Oncol; 2019 Jul; 14(7):e145-e146. PubMed ID: 31235038
[No Abstract] [Full Text] [Related]
20. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
